Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Merck & Co (NY: MRK )

129.95 +2.95 (+2.32%)
Streaming Delayed Price Updated: 12:38 PM EDT, Apr 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Merck & Co

< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Merck Announces Second-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Completes Tender Offer to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Merck Named One of America’s Most JUST Companies by JUST Capital and CNBC, Industry Leader in Pharmaceuticals and Biotech
From Merck & Co., Inc.
Via Business Wire
Merck to Hold Fourth-Quarter and Full-Year 2022 Sales and Earnings Conference Call February 2
From Merck & Co., Inc.
Via Business Wire
Merck to Present at the 41st Annual J.P. Morgan Healthcare Conference
From Merck & Co., Inc.
Via Business Wire
Big Health Care Stocks to Watch in the New Year
Here are three health care stocks to watch as the New Year begins. Two have a moderate Buy rating while one is a Hold, for now. 
Via MarketBeat
Merck to Present at the Goldman Sachs Healthcare CEOs Unscripted Conference
From Merck & Co., Inc.
Via Business Wire
Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer
From Merck & Co., Inc.
Via Business Wire
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Approved in the EU as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Seagen, Astellas and Merck Announce FDA Acceptance of sBLAs for PADCEV® (enfortumab vedotin-ejfv) with KEYTRUDA® (pembrolizumab) for the First-Line Treatment of Certain Patients With Locally Advanced or Metastatic Urothelial Cancer
From Seagen Inc.
Via Business Wire
AstraZeneca and Merck Provide Update on US Regulatory Review of LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone as Treatment of Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Moderna and Merck Announce mRNA-4157/V940, an Investigational Personalized mRNA Cancer Vaccine, in Combination with KEYTRUDA(R) (pembrolizumab), Met Primary Efficacy Endpoint in Phase 2b KEYNOTE-942 Trial
Via ACCESSWIRE
Merck Begins Tender Offer to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations:) Apollo Endosurgery, Inc. (Nasdaq - APEN), Imago BioSciences, Inc. (Nasdaq - IMGO), Opiant Pharmaceuticals Inc. (Nasdaq - OPNT), Benefitfocus, Inc. (Nasdaq - BNFT)
From Brodsky & Smith LLC
Via GlobeNewswire
Merck to Present Data From Its Hematology Portfolio and Promising Pipeline at the 64th American Society of Hematology (ASH) Annual Meeting
From Merck & Co., Inc.
Via Business Wire
Research and Development of Advanced Therapeutics for Ovarian Cancer Fueling Hope
EQNX::TICKER_START (OTCQB:BVAXF),(NASDAQ:CTIC),(NASDAQ:SGEN),(NYSE:MRK),(NASDAQ:IMGN) EQNX::TICKER_END 
Via FinancialNewsMedia
Topics Intellectual Property
Exposures Intellectual Property
Merck Announces First-Quarter 2023 Dividend
From Merck & Co., Inc.
Via Business Wire
Merck Announces Phase 3 KEYNOTE-859 Trial Met Primary Endpoint of Overall Survival in Patients With HER2-Negative Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma
From Merck & Co., Inc.
Via Business Wire
Imago BioSciences (NASDAQ: IMGO) to be Acquired by Merck (NYSE: MRK) for $1.35 Billion
Imago BioSciences, Inc. (NASDAQ: IMGO) is engaged as a clinical-stage biopharmaceutical company, which is focused on the research and development 
Via Spotlight Growth
Merck to Present at the 5th Annual Evercore ISI HealthCONx Conference
From Merck & Co., Inc.
Via Business Wire
Merck to Acquire Imago BioSciences, Inc.
From Merck & Co., Inc.
Via Business Wire
Can AbbVie Grow Revenue When Humira Biosimilars Hit The Market?
Shares of AbbVie have been in rally mode since late October. The company has newer drugs whose revenue could make up for declines due to Humira's patent expiry. 
Via MarketBeat
Topics Intellectual Property
Exposures Intellectual Property
LYNPARZA® (olaparib) in Combination With Abiraterone and Prednisone or Prednisolone Receives Positive Opinion From EU CHMP as Treatment for Certain Patients With Metastatic Castration-Resistant Prostate Cancer
From Merck & Co., Inc.
Via Business Wire
Biotechs with Evolving Therapies Have Potential to Revolutionize Treatments for Pancreatic Cancer
EQNX::TICKER_START (NASDAQ:ONCY),(TSX:ONC),(NASDAQ:MACK),(NASDAQ:NRBO),(NYSE:MRK),(NASDAQ:RNAZ), EQNX::TICKER_END 
Via FinancialNewsMedia
Rising Incidence of Pancreatic Cancer Driving Demand for Advanced Treatment Therapies
Palm Beach, FL – November 7, 2022 – FinancialNewsMedia.com News Commentary – While there is no cure for pancreatic cancer in the pancreatic cancer treatment market, new treatment options abound, and... 
Via FinancialNewsMedia
Exposures COVID-19
Reductions in Certain Types of HPV-Related Cervical and Non-Cervical Diseases in Women and Men Observed with Real-World Use of Merck's GARDASIL® in Systematic Literature Review of 138 Studies
From Merck & Co., Inc.
Via Business Wire
Why Investors Are Suddenly Excited About Vaxcyte
Vaxcyte, Inc. is a small cap biotech company that catapulted back to mid-cap land with a stunning 110% surge — and may not be done yet. 
Via MarketBeat
Exposures COVID-19
Can Big Data Make Patient Care More Personalized And Effective?
It’s fairly common knowledge that our data is being used to learn and predict human behavior, often to the benefit of the companies who aggregate and analyze this data. But can these diverse data sets... 
Via TheNewswire.com
Merck Stock Price Rose as the Company Raised Its Full-Year Outlook Due to the Success of Keytruda
Merck & Co Inc (NYSE:MRK) A rise in demand for blockbuster cancer treatment Keytruda and human papillomavirus vaccination Gardasil contributed to Merck & Co Inc (NYSE: MRK) higher-than-expected sales... 
Via PressReach
Topics Intellectual Property
Exposures Intellectual Property
Merck Beats Expectations for the Third Quarter as Sales of the COVID-19 Tablet Are Partially Offset by Keytruda
Merck stock was trading at $100.91 as of 09:49 AM EDT. After reporting stronger-than-anticipated financial results for the third quarter of 2022, Merck (NYSE:MRK) saw its pre-market trading price... 
Via PressReach
Exposures COVID-19
< Previous 1 2 3 4 5 6 7 8 9
...
16 17 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.